REGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Rating of “Moderate Buy” by Brokerages

REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the five ratings firms that are presently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $35.67.

A number of analysts have recently weighed in on the stock. Chardan Capital lowered their price target on shares of REGENXBIO from $61.00 to $55.00 in a report on Thursday, May 4th. Robert W. Baird began coverage on shares of REGENXBIO in a report on Thursday, June 1st. They issued an “outperform” rating and a $42.00 target price on the stock. Finally, StockNews.com started coverage on shares of REGENXBIO in a research report on Thursday, May 18th. They issued a “hold” rating on the stock.

Get REGENXBIO alerts:

REGENXBIO Price Performance

Shares of RGNX opened at $18.81 on Monday. REGENXBIO has a one year low of $17.02 and a one year high of $35.73. The company has a market cap of $817.67 million, a P/E ratio of -3.01 and a beta of 1.09. The firm has a 50 day simple moving average of $19.22 and a two-hundred day simple moving average of $20.34.

REGENXBIO (NASDAQ:RGNX – Get Free Report) last issued its quarterly earnings results on Wednesday, May 3rd. The biotechnology company reported ($1.53) EPS for the quarter, missing analysts’ consensus estimates of ($1.52) by ($0.01). REGENXBIO had a negative net margin of 246.50% and a negative return on equity of 49.69%. The firm had revenue of $19.10 million for the quarter, compared to the consensus estimate of $31.29 million. During the same period last year, the company posted ($1.62) EPS. The business’s revenue was down 14.0% compared to the same quarter last year. On average, analysts expect that REGENXBIO will post -4.49 earnings per share for the current fiscal year.

Institutional Investors Weigh In On REGENXBIO

Large investors have recently added to or reduced their stakes in the stock. Raymond James Financial Services Advisors Inc. increased its holdings in shares of REGENXBIO by 55.3% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 64,906 shares of the biotechnology company’s stock worth $1,297,000 after buying an additional 23,119 shares during the last quarter. Raymond James & Associates grew its holdings in REGENXBIO by 18.3% during the 2nd quarter. Raymond James & Associates now owns 19,914 shares of the biotechnology company’s stock valued at $398,000 after purchasing an additional 3,083 shares during the last quarter. PAX Financial Group LLC grew its holdings in REGENXBIO by 16.2% during the 2nd quarter. PAX Financial Group LLC now owns 30,507 shares of the biotechnology company’s stock valued at $610,000 after purchasing an additional 4,243 shares during the last quarter. Louisiana State Employees Retirement System grew its holdings in REGENXBIO by 12.5% during the 2nd quarter. Louisiana State Employees Retirement System now owns 19,800 shares of the biotechnology company’s stock valued at $396,000 after purchasing an additional 2,200 shares during the last quarter. Finally, Harbor Capital Advisors Inc. boosted its position in REGENXBIO by 81.7% in the 2nd quarter. Harbor Capital Advisors Inc. now owns 44,106 shares of the biotechnology company’s stock valued at $882,000 after buying an additional 19,830 shares during the period. Institutional investors own 89.57% of the company’s stock.

REGENXBIO Company Profile

(Get Free Report

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.

See Also

• Five stocks we like better than REGENXBIO
• How to Invest in Music Stocks
• MarketBeat Week in Review – 7/24 – 7/28
• Energy and Oil Stocks Explained
• Can SAIA Continue its Stratospheric Rally?
• Conference Calls and Individual Investors
• Why Markets Are Loving Exxon Mobil, Despite The Earnings Dip

Receive News & Ratings for REGENXBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO and related companies with MarketBeat.com's FREE daily email newsletter.